

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/57, C07K 16/40, G01N 33/573, C12N 9/64		A2	(11) International Publication Number: WO 97/29199
			(43) International Publication Date: 14 August 1997 (14.08.97)
(21) International Application Number: PCT/US97/01911		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(22) International Filing Date: 6 February 1997 (06.02.97)		Published <i>Without international search report and to be republished upon receipt of that report.</i>	
(30) Priority Data: 08/595,945 6 February 1996 (06.02.96) US			
(71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).			
(72) Inventors: DOWELL, Barry, Lee; 197 Knightsbridge Drive, Mundelein, IL 60060 (US). BRIDON, Dominique, P.; 2167 Bay Street, San Francisco, CA 94123 (US). QIU, Xiaoxing; 752 Sierra Place, Gurnee, IL 60031 (US). LILJA, Hans; Holländarevagen 28, S-236 00 Hollviken (SE). PIIRONEN, Timo, Petteri; Frantsinkatu 4 B 8, FIN-20380 Turku (FI). VIHINEN, Mauno, Antero; Alkutie 27 C, FIN-00660 Helsinki (FI). PETERSSON, Immanuel, Kim, Sverker; Ti- ilentekijankatu 14 E 20, FIN-20810 Turku (FI).			
(74) Agents: BECKER, Cheryl, L. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).			
(54) Title: PROSTATE SPECIFIC ANTIGEN PEPTIDES AND USES THEREOF			
(57) Abstract			
<p>The present invention relates to peptides which may be used, for example, in the detection of free and complexed Prostate Specific Antigen and thus in the diagnosis of prostate cancer.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

PROSTATE SPECIFIC ANTIGEN PEPTIDES
AND USES THEREOF

5

BACKGROUND OF THE INVENTION

Technical Field

The present invention relates to peptides which may be used,
10 for example, in the detection of free and complexed Prostate
Specific Antigen (PSA) and thus in the diagnosis of prostate
cancer.

Background Information

15 Prostate specific antigen (PSA) is a low molecular weight
glycoprotein of approximately 30 kilodaltons (kD) produced mainly
by prostatic glandular epithelial cells. PSA is a member of the
human tissue kallikrein gene family, which consists of three
genes, hKLK1, hKLK2, and hKLK3. The protein product of these
20 genes are pancreatic-kidney kallikrein (hK1), human glandular
kallikrein (hK2) (previously known as hGK-1), and PSA (hK3). PSA
is a serine protease and exhibits a chymotrypsin-like specificity
cleaving at a hydrophobic residue (see Chu et al., J. Urol.
141:152-56 (1989)). The other two kallikreins have trypsin-like
25 specificity. These three genes are located on chromosome 19.
The expression of both PSA and hK2 are under androgen control.
The protein for hK2 has not been isolated, and its potential
clinical utility has not been determined (McCormack et al.,
Urology 45:729-44 (1995); see also copending U.S. patent
30 application no. 08/394,033).

PSA is produced in the prostate and occurs in high
concentrations in prostate and seminal fluid. It also occurs in
urine and in serum. The concentration of serum PSA in the normal
35 male increases with age. Increased levels of serum PSA are found
in benign prostatic hyperplasia (BPH), prostatitis and prostate
cancer. The expression of PSA in most females is negative or
very low. While PSA isolated from seminal fluid or prostatic

tissue occurs predominately as the 30kD form of PSA, PSA in the serum occurs in various forms. A small portion of serum PSA occurs as low molecular weight or free PSA. The majority of immunodetectable PSA occurs as a 100 kD complex of PSA and
5 alpha-1-antichymotrypsin (ACT) otherwise known as complexed PSA (PSA-ACT). Another PSA complex formed with alpha-2-macroglobulin is not detectable by current immunoassays. PSA complexes with these protease inhibitors through its serine protease active site. Presumably, the free PSA in serum is inactive PSA, since
10 serum contains an excess of protease inhibitors (McCormack et al., Urology 45:729-44 (1995), Partin et al., J. Urol. 152:1358-68(1994), Lilja et al., Clin. Chem. 37:1618 (1991), Stenman et al., Cancer Res. 51:222 (1991) and WO 92/09136).

15 Serum PSA has become the most clinically useful tumor marker in prostatic disease. PSA is used to monitor the response to therapy and detect early relapses for prostate cancer. When prostate cancer is treated with radiation, surgery or androgen-deprivation, the serum levels of PSA decrease. The level that
20 they decrease to following therapy is correlated to prognosis and survival. When used following radical prostatectomy, the PSA level following successful treatment should decrease to zero, since the prostate is the only significant source of PSA. This allows PSA to be a very sensitive marker for tumor relapse
25 following surgery. PSA has also been used to help stage patients. It has been shown that PSA level correlates with tumor volume, but is not accurate enough to independently stage the disease; however, PSA level is useful in combination with other clinical and pathological parameters (Partin et al., J. Urol.
30 152:1358-68 (1994)).

A major development in the use of PSA is its application to the early detection of prostate cancer prior to the appearance of clinical symptoms. Prior to the advent of the use of PSA, the
35 digital rectal exam was used (DRE). This method was not very sensitive or specific. In addition, many tumors detected by DRE were too large to cure. The use of PSA in conjunction with DRE

as an early detection method has been validated in several clinical studies. Typically, a cutoff of 4.0 ng/mL has been used as the upper limit of normal. Above this level, about 33% of biopsies are positive, while above 10 ng/mL, approximately 67% are positive. PSA levels above a value of 4.0 can be due to prostatitis or benign prostate hypertrophy (BPH). Most men over 50 years old have some evidence of BPH. Age-specific reference ranges for PSA have been suggested as a way to improve PSA's use in early detection (Parkin, et al., J. Urol. 152:1358-68 (1994)).

10

Patients with PSA below 4.0 ng/mL with a normal DRE are considered normal, while those above 10 ng/mL are considered likely to have prostate cancer. Therefore, the gray zone is between 4 and 10 ng/mL. Several methods have been devised to improve the specificity of PSA in early detection. They include: 1) the use of age-specific reference ranges, 2) the use of PSA changes over time, 3) the use of PSA density and 4) the use of ratios of PSA forms. It has been shown that the use of ratios of free PSA levels divided by total PSA levels or ratios of PSA-ACT complex levels divided by total PSA levels can improve the specificity of PSA for cancer. This is because the serum of patients with prostate cancer tend to have less free PSA than do the serum of men with BPH (McCormack et al., Urology 45:729-44 (1995), Partin et al., J. Urol. 152:1358-68 (1994), Lilja et al., Clin. Chem. 37:1618 (1991), Stenman et al., Cancer Res. 51:222 (1991) Christensson et al., J. Urol. 150:100-105 (1993) and WO 92/01936).

The peptides of the present invention will enable the production of antisera necessary to determine the amount of total PSA, free PSA and PSA-ACT complex present in a sample and thus improve the ability of the clinician to distinguish, for example, between BPH and prostate cancer in a patient. The proper course of treatment may then be undertaken. This use and other uses of the present peptides will be described in further detail below.

All U.S. patents and publications referred to herein are hereby incorporated in their entirety by reference.

SUMMARY OF THE INVENTION

5

The present invention relates to a purified peptide comprising an amino acid sequence of approximately 10-20 residues which is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2. Alternatively, the sequence of the peptide may be identical to the sequence of both the amino acid sequence of a region of PSA and hK2. These peptides may, for example, be selected from the group consisting of ABT1 (SEQ. ID. No:1), ABT2 (SEQ. ID. No:2), ABT3 (SEQ. ID. No:3), ABT4 (SEQ. ID. No:4), ABT5 (SEQ. ID. No:5), ABT6 (SEQ. ID. No:6), ABT7 (SEQ. ID. No:7), ABT8 (SEQ. ID. No:8), ABT9 (SEQ. ID. No:9), ABT10 (SEQ. ID. No:10), ABT11 (SEQ. ID. No:11), ABT12 (SEQ. ID. No:12), ABT13 (SEQ. ID. No:13), ABT15 (SEQ. ID. No:15) and ABT16 (SEQ. ID. No:16).

20

Furthermore, the present invention also includes an antibody specific for free PSA produced in response to immunization by a peptide of the present invention. Examples of such peptides are ABT6 and ABT1. Antibodies against these peptides may be monoclonal or polyclonal.

25

Additionally, the present invention relates to an antibody specific for total PSA produced in response to immunization by a peptide selected from the group consisting of ABT4, ABT14 and ABT16. Again, such antibodies may be monoclonal or polyclonal.

30

Moreover, the present invention also encompasses a method for detecting PSA in a test sample suspected of containing PSA. This method comprises the steps of:

- a) contacting the test sample with an antibody or fragment thereof which specifically binds to at least one site on a peptide or antigen for a time and under conditions sufficient to allow for the formation of antigen/antibody complexes; b) adding

a probe antibody to the resulting antigen/antibody complexes for a time and under conditions sufficient to allow the probe to bind to bound antigen, wherein the probe binds to a second site on the peptide or antigen; and

- 5 c) determining the amount of bound probe and thus the amount of PSA in the test sample. The PSA peptide or antigen comprises an amino acid sequence of approximately 10-20 residues wherein said sequence is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the
- 10 amino acid sequence of hK2. For example, the peptide or antigen may be selected from the group consisting of ABT2, ABT4, ABT6, ABT1, ABT7, and ABT16. The antibody of step (a) may be attached to a solid phase, and the antibody of step (c) may be labelled with a radioactive isotope. Additionally, one antibody may be
- 15 specific for free PSA and the other antibody may be specific for total PSA, or both antibodies may be specific for total PSA.

The present invention also includes another method of detecting PSA in a test sample suspected of containing PSA. The

20 method comprises the steps of: a) contacting the test sample with an antibody or fragment thereof which specifically binds to at least one antigen or peptide derived from PSA for a time and under conditions sufficient to allow for the formation of antigen/antibody complexes; b) adding a labeled free PSA to the

25 resulting test sample-antibody mixture of step (a); and c) determining the amount of PSA in the test sample by assessing the amount of competition between the PSA in the test sample and the labeled free PSA. If free PSA is to be detected, the antibody of step (a) binds specifically to free PSA, and if total PSA is to

30 be detected, the antibody of step (a) binds to total PSA. The peptide or antigen comprises an amino acid sequence of approximately 10-20 residues wherein the sequence is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2.

35 For example, the peptide or antigen is selected from the group consisting of ABT2, ABT4, ABT6, ABT1, ABT7, and ABT16.

Also, the present invention encompasses a kit for determining the presence of PSA in a test sample comprising a container containing an antibody produced in response to immunization by a peptide. The peptide comprises an amino acid sequence of approximately 10-20 residues which is identical to the amino acid sequence of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2. The peptides used to produce the antibodies may be selected from, for example, ABT2, ABT4, ABT6, ATB1, ABT7 and ABT16.

10

Another kit of the present invention, which may be used for determining the presence of PSA in a test sample, comprises: a) an antibody or fragment thereof which specifically binds to at least one site on PSA; and b) a probe antibody wherein said probe binds to a second site on the PSA. The peptide used to produce the antibody comprises an amino acid sequence of approximately 10-20 residues wherein the sequence is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2. For example, the peptide may be selected from the group consisting of ABT2, ABT4, ABT6, ABT1, ABT7, and ABT16.

15

20

The present invention also includes a kit for determining the presence of free PSA in a test sample comprising: a) an antibody or fragment thereof which specifically binds to a peptide comprising an amino acid sequence of approximately 10-20 residues wherein the sequence is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2; and b) labeled free PSA. The peptide used to produce the antibody may be ABT6 or ABT1.

25

30

Additionally, the present invention includes a purified peptide derived from PSA comprising an amino acid sequence of approximately 10-20 residues which is identical to the amino acid sequence of a region of PSA and identical to the amino acid

35

sequence of any region of hK2. An example of such a peptide is ABT14 (SEQ. ID. No:14).

5

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 depicts designed PSA peptides. (A) Locations of the designed peptides on the 3D model of PSA, peptide segments were labeled by the ABT numbering. (B) Sequence and structural
10 alignment of PSA and hK2 (see SEQ. ID. No:17 and SEQ. ID. No:18, respectively). Designed PSA peptide sequences were labeled by the ABT numbering; the nonhomologous or nonidentical residues were indicated in bold in hK2 and shaded in PSA. In addition,
15 two hK2 peptides derived from the hK2 sequence were also labeled as hK2a and hK2b.

Figure 2 depicts (A) the inhibition of free PSA specific monoclonal antibodies and of monoclonal antibodies which preferentially detect free PSA and (B) the titration curves
20 showing the binding specificity of mAb 2E9, an antibody which preferentially detects free PSA to ABT6 peptide and PSA, but not to the hK2b peptide.

Figure 3 depicts (A) the inhibition of total PSA specific
25 mAbs binding to PSA by ABT4 peptide, (B) the inhibition of total PSA specific mAbs binding to PSA by ABT14 and ABT16 peptides and (C) the titration curves showing the binding specificity of mAb H164 to ABT4 peptide and PSA, but not to the hK2a peptide.

30 Figure 4 depicts the specific binding of the alkaline phosphatase-labeled goat anti-PSA antiserum to the synthetic PSA peptides.

Figure 5 depicts the titration curves showing the binding
35 specificity of rabbit anti-ABT6 antiserum to both ABT6 peptide and PSA, but not to hK2b peptide.

Figure 6 depicts the titration curves comparing the binding affinity of rabbit anti-ABT4 antiserum to ABT4 peptide, PSA, and hK2a peptide. The affinity rank is ABT4 > PSA > hK2a.

5

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a purified peptide comprising an amino acid sequence or fragment thereof of approximately 10-20 residues which is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2. Alternatively, the amino acid sequence of the peptide may be identical to both the sequence of a region of PSA and a region of hK2. These peptides may be used for different diagnostic and therapeutic purposes. (It should be noted that terminal cysteine groups may be added to "identical" peptides to perform cyclization. "Identical" peptides may also be attached to carrier molecules through the use of cysteine groups.)

20 The term "identical" is used to describe the degree of relatedness between two polynucleotides or polypeptide sequences. The techniques for determining amino acid sequence "identity" are well-known in the art and include, for example, directly determining the amino acid sequence of the peptide in question, for example, and comparing it to the sequences provide herein. In particular, "identity" refers to an exact match-up of the amino acid sequences of two entities, for example, a peptide of the invention and PSA and/or hK2. "Nonidentical" refers to the lack of an exact match-up of the amino acid sequences in question. The programs available in the Wisconsin Sequence Analysis Package, Version 8 (available from the Genetics Computer Group, Madison, Wisconsin, 53711), for example, the GAP program, are capable of calculating the identity (and similarity) between two polynucleotide or two polypeptide sequences. Other programs for calculating identity between two nucleotide or amino acid sequences are known in the art.

The peptides of the invention were selected by constructing three-dimensional models of PSA and hK2 (Bridon et al., Urology 45:801-806 (1995) & Vihinen, M., Biochem. Biophys. Res. Commun. 204:1251-1256 (1995)) and then determining which of the exposed regions in the model possessed particular characteristics.

More specifically, a model of PSA was first generated by extrapolating from crystallographic coordinates and amino acid sequences of homologous members of the serine protease family using standard comparative methods.

Subsequently, peptides were selected which appeared to be close to the surface of the molecule based upon direct visualization. Thus, antibodies to such exposed surface peptides are capable of readily binding thereto. Residues which were buried in the protein were not selected.

Additionally, secondary structure was used as a criteria in selecting the peptides disclosed herein. More specifically, peptides were chosen which preferably possessed beta-turns, and protruding loops, as such a structural characteristic has been correlated with production of an immunological response. (See e.g., Krchnak et al., Methods in Enzymology 178:586-611 (1989)).

High flexibility and high hydrophilicity were also considered. Such characteristics are associated with immunogenicity and thus the ability to elicit production of antibodies. In particular, the method of Karplus and Shultz was utilized in order to predict high flexibility (see Karplus et al., Naturwissenschaften 72:212-13 (1985)). The method of Hopp and Woods was utilized in order to predict high hydrophilicity (see Hopp et al., Proc. Natl. Acad. Sci. USA 78:3824-28 (1981)).

Another factor which was considered in the selection process involves the presence of a naturally occurring disulfide bridge in the peptide and/or the possibility that a beta-coil or turn could be kept in the proper conformation by adding a disulfide

bridge within the peptide. Such properties cause the cyclic peptide to more closely mimic the three dimensional configuration of the PSA protein and were therefore useful in the selection process.

5

After the peptides were selected from the three-dimensional model based upon the above-criteria, the sixteen sequences selected were synthesized in their linear conformations. Several sequences were also produced in their cyclic conformations. Such
10 cyclic forms may act as better immunogens than their linear counterparts.

15

The designations of the peptides, their amino acid sequences and their molecular weights are illustrated in Table 1 below.

Table 1

Synthetic PSA Peptides

Peptide	Sequence	M.W. verified by MS
ABT1 (SEQ. ID. NO:1)	CNRFLRPGDDSSC	1468
ABT2 (SEQ. ID. NO:2)	CWGSIEPEEFLTPKKLC	1980
ABT3 (SEQ. ID. NO:3)	CAQVHPQKVTKFMLC	1732
ABT4 (SEQ. ID. NO:4)	CLLGRHSLFHPEDTGQC	1912
ABT5 (SEQ. ID. NO:5)	TSWGSEPCALPERPSLY	1893
ABT6 (SEQ. ID. NO:6)	CMSLLKNRFLRPGDDSC	1955
ABT7 (SEQ. ID. NO:7)	SEPAELTDAVKV	1258
ABT8 (SEQ. ID. NO:8)	HYRKWIKDTIVANA	1714
ABT9 (SEQ. ID. NO:9)	AGRWTGGKSTCSGDSG	1527
ABT10 (SEQ. ID. NO:10)	SHSFPHPLYDMSLLK	1671
ABT11 (SEQ. ID. NO:11)	VMDLPTQEPALGTTC	1575
ABT12 (SEQ. ID. NO:12)	HSQPWQVLVASRGRAV	1790
ABT13 (SEQ. ID. NO:13)	PQWVLTAAH CIRNKS	1724
ABT14 (SEQ. ID. NO:14)	VGGWECEKHSQPWQ	1670
ABT15 (SEQ. ID. NO:15)	SNDVCAQVHPQKVTKFMLC	2148
ABT16 (SEQ. ID. NO:16)	DLHVISNDVCAQVHPQK	1902

MS=mass spectroscopy

Although all of the peptides noted above may be used to
5 generate either monoclonal or polyclonal antibodies reactive with
PSA, seven of the peptides, namely ABT4, ABT14, ABT6, ABT1, ABT2,
ABT16 and ABT7 show specific binding to several known anti-PSA
monoclonal antibodies and can therefore be used, for example, as
immunogens to elicit epitope-specific polyclonal as well as
10 monoclonal antibodies. An epitope-specific polyclonal antibody
is an antibody that is generated with an immunogen representing a
small segment of amino acid residues from the parent protein, a
protein which has immunogenic properties (i.e., is able to elicit
an immune response). The small segment or peptide is considered
15 to be an epitope.

The structure and properties of these seven peptides are as
follows:

20 ABT6 is present in the three-dimensional model of PSA as a
protruding loop near the catalytic triad in the active site of
PSA (see Fig. 1A). It contains a PSA specific epitope which is
blocked by ACT in the PSA-ACT complex, and its amino acid
sequence is not identical to hK2. Moreover, it is also
25 immunogenic and therefore has the ability to elicit antibodies
(see Fig. 5).

ABT1 is a short version of ABT6. ABT1 contains the same
sequence as ABT6 except that five amino acids at the N-terminal
30 (MSLLK) and the serine amino acid at the C-terminal of ABT6 are
not included in ABT1 (Figure 1B). Inhibition studies show that
ABT1 inhibits three monoclonal antibodies: 9B10 (40 %
inhibition), 6:3 (23 % inhibition) and 30:5 (50 % inhibition).
Similar to ABT6, ABT1 contains four amino acids that are not
35 identical to hK2. Therefore, ABT1 should be a PSA specific
epitope which is blocked by ACT in the PSA-ACT complex.

ABT4 is present in the three-dimensional model of PSA as a loop and beta-sheet structure distant from the catalytic triad. It is a PSA specific epitope which is not blocked by ACT in the PSA-ACT complex and has an amino acid sequence that is not
5 identical to hK2. It too is immunogenic (see Fig. 6).

ABT14 is present as the N-terminal sequence of PSA. It contains an epitope of PSA and is not blocked by ACT in the PSA-ACT complex. Its amino acid sequence is identical to PSA and hK2
10 (see Fig. 1B).

ABT16 is present in the three-dimensional model of PSA as an alpha-helical structure. It contains an epitope which is not blocked by ACT in the PSA-ACT complex and may be PSA specific due
15 to its lack of identity with the amino acid sequence of hK2 (see Fig. 1B).

ABT2 is present as a loop structure in the three-dimensional model of PSA. It is an epitope which is not blocked by ACT in
20 the PSA-ACT complex. This epitope may also be PSA specific due to its lack of identity with the amino acid sequence of hK2 (see Fig. 1B).

ABT7 is present in the three-dimensional model of PSA as a
25 loop structure away from the catalytic triad. It is an epitope which is not blocked by ACT in the PSA-ACT complex, and may be PSA specific due to its lack of identity with the amino acid sequence of hK2 (see Fig. 1B).

30 In particular, the peptides of the present invention which are reactive with antibodies specific for free PSA (i.e., "free PSA-associated epitopes") can be used to generate antibodies (i.e., "free, specific antibodies") in polyclonal and monoclonal systems by injection with peptide-carrier proteins or in other
35 immunogenic forms. Examples of such free PSA-associated epitope are ABT6 and ABT1. Suitable peptide carrier proteins include, for example, those proteins which have a sufficient molecular

weight such that they are immunogenic. Examples include but are not limited to bovine serum albumin, keyhole limpet hemocyanin, ovalbumin and synthetic carriers such as poly-L-lysine or poly-L-glutamine which allow for multiple attachments of the peptide.

- 5 (For a general discussion of generating antisera by linking peptides to carriers, see Methods in Molecular Biology, ed. J. Walker, Vol. 32, pp. 389-400 (1994).)

10 Additionally, the peptides of the invention which are reactive with antibodies specific for total PSA (i.e., "total PSA-associated epitopes") may be used to generate "total PSA antibodies" in polyclonal and monoclonal systems by injection with peptide-carrier proteins or in other immunogenic forms. Examples of such total PSA-associated epitopes include ABT4,
15 ABT14 and ABT16.

It should be noted that "free associated" antibodies or epitopes are those antibodies and the epitopes associated with them that demonstrate partial or essentially total specificity
20 for free PSA as compared to PSA-inhibitor complexes, the most common of these being PSA-alpha-1-antichymotrypsin (PSA-ACT) and PSA-alpha-2-macroglobulin (PSA-A2M).

25 Additionally, "total" PSA antibodies or epitopes are those antibodies and the epitopes associated with them that demonstrate the ability to bind to both PSA and PSA-ACT complexes in a significantly equivalent manner.

The advantage of being able to measure the level of free and
30 total PSA is quite significant. As noted above, the ratio of free PSA to total PSA is lower in patients with prostate cancer than in patients with BPH. Thus, the addition of a free to total PSA ratio value to the results of a digital rectal examination can aide in the early detection of prostate cancer and thus reduce
35 the number of biopsies required (McCormack et al., Urology 45:729-44 (1955), Partin et al., J. Urol. 152:1358-68 (1994),

Lilja et al., Clin. Chem. 37:1618 (1991), Christinesson et al.,
5 J. Urol. 150:100-105 (1993)).

The present invention also encompasses kits containing
5 antibodies produced in response to, or directed against, the
peptides of the invention. Such antibodies may be elicited, for
example, in response to immunization with one or more of the
peptides.

10 It should be noted that "total PSA" is used to describe the
ability of an immunoassay to recognize immunologically detectable
forms of PSA, especially free PSA and PSA-ACT complexes, the two
most common PSA forms in serum. Since the percentage of free PSA
and PSA-ACT varies from man to man, total PSA assays are
15 necessary to detect both forms (McCormack et al., Urology 45:729-
44 (1995) and Partin et al., J. Urol. 152:1358-68 (1994)).

Also, those free PSA-associated and total PSA-associated
peptides of the invention which are not identical with hK2 can be
20 used to generate PSA-specific, non-hK2 cross-reactive antibodies
to free PSA or total PSA in polyclonal and monoclonal systems by
injection with peptide-carrier proteins or in other immunogenic
forms. (Since there is a high degree of amino acid and structural
identity between PSA and hK2, it is difficult to produce
25 antibodies which are not cross-reactive.)

Additionally, free PSA-specific immunoassays can be
configured using a combination of free specific antibodies and
total PSA antibodies referred to above. (Currently available
30 total PSA antibodies can be substituted for the total PSA
antibodies of the present invention.)

In particular, a sandwich assay can be utilized with one
free specific antibody and one total PSA antibody generated using
35 the appropriate peptides of the invention. A typical two-step
sandwich assay for PSA consists of a first antibody to PSA
immobilized on a carrier (e.g., a microtiter plate, a polystyrene

bead, and a latex microparticle) to which the specimen, controls or calibrators containing PSA are added. The PSA in these samples binds to the carrier bound PSA antibody during an incubation phase. The unbound material is removed by washing, for example, with buffer. A probe antibody to PSA is then added and binds to a second site on the PSA during an incubation phase. The excess probe antibody is removed by washing with buffer. The probe antibody may be labelled with a radioactive isotope, such as I¹²⁵, or with an enzyme, for example, horseradish peroxidase, alkaline phosphatase or glucose oxidase. The amount of probe bound by the PSA can be determined by determining the level of radioactivity or by adding an enzyme substrate and detecting the product formed. The amount of PSA is then determined from a calibration curve using standards with known PSA levels.

15

It should also be noted that the invention includes a kit which can be used to carry out the above-described sandwich assay. Such a kit may include, for example, an antibody or fragment thereof which specifically binds to at least one site on PSA and a probe antibody which binds to a second site on PSA. The antibodies are generated using the peptides of the invention.

A one-step assay combines the capture antibody, probe antibody, and PSA containing samples in one incubation step followed by a wash step and a read step. For a free PSA specific assay, either the probe or carrier antibody must be free specific (Chan et al., Clin. Chem. 33:1916-1920 (1987), Ambruster, Clin. Chem. 39:181-195 (1993), Lilja et al., Clin. Chem. 37:1618 (1991) and Christenesson et al., J. Urol. 158:100-105 (1993)).

30

Furthermore, the peptides of the present invention may be used to generate antibodies for a competitive assay for free PSA. More specifically, the assay involves the use of one free specific antibody and labelled free PSA. (Labelled free peptide can replace labelled free PSA if more convenient.)

35

In a competitive assay for free PSA, the sample, controls or calibrators are incubated with an antibody to free PSA. Following this step or simultaneously with this step, radiolabeled purified free PSA is added. (In addition to the use of a radioactive label, the PSA may also be labeled with other reporter molecules such as enzymes or chemicals which generate chemiluminescence or fluorescence (see e.g., Chan et al., Clin. Chem. 33:1916-20 (1987))). A second antibody to the free PSA antibody, for instance, goat anti-mouse IgG, if the free PSA antibody is a mouse monoclonal, is added to precipitate the free PSA antibody and any PSA that is bound. Alternatively, the second antibody can be attached to a solid phase, such as, for example, a latex microparticle or polystyrene bead. The mixture is washed with buffer, and the amount of radioactivity determined. The amount of PSA in the sample is determined by comparing the amount of competition of the PSA in the sample for the binding of the labeled PSA. The concentration of PSA is determined using a calibration curve consisting of standards with known levels of PSA (Chan et al., Clin. Chem. 33:1916-1920 (1987)).

The invention includes a kit which utilizes the competitive assay components described above. More specifically, such a kit may include an antibody or fragment thereof which binds to at least one of the peptides of the invention. The kit would also include, for example, labelled free PSA.

Also, a total PSA specific immunoassay can be generated using a combination of two total PSA-associated antibodies, raised against the peptides of the present invention, one or both of which may be non-hK2 cross-reactive antibodies. Alternatively, one of the above-listed antibodies may be used in combination with a currently available total PSA antibody. (The use of a non-hK2 cross-reactive antibody generates a PSA, non-hK2 cross-reactive assay.) The total PSA specific assay is performed as described above for a free PSA sandwich assay except both antibodies must be reactive with total PSA. If both of the

antibodies are reactive with total PSA and with hK2, the assay that is generated will detect both PSA and hK2. If either the probe or capture antibody is specific for PSA (non-hK2 reactive), the assay will only detect total PSA. The advantage of the first
5 format is that both kallikriens produced by the prostate (i.e., PSA and hK2) are detected. The advantage of the second format is that the assay will be specific for the PSA molecule only.

Additionally, a competitive assay for total PSA can be
10 generated using one of the total PSA antibodies raised against a peptide of the invention, or one of the PSA specific, non-hK2 cross-reactive antibodies raised against a peptide of the invention, and labelled free or complexed PSA. Labeled free peptide can replace labelled free PSA in the assay. (Again, the
15 use of a non-hK2 cross-reactive antibody generates a PSA, non-hK2 cross-reactive assay.) The steps of the assay are the same as for the competitive free PSA assay, except that a total PSA antibody or a total PSA, non-hK2 reactive antibody is used instead of an antibody to free PSA.

20

Furthermore, an immunoassay for the PSA-ACT complex can be generated using a total PSA antibody (which may possibly be a non-hK2 cross-reactive antibody) to form a sandwich with currently available antibodies to ACT. As noted above, the PSA-
25 ACT complex is the major form of PSA in the serum. An assay for PSA-ACT is more specific than a total PSA assay in that one "type" of molecule is being detected. Thus, using assays for free PSA and PSA-ACT, it is possible to detect the two major forms of PSA independently.

30

The use of ratios of PSA-ACT to total PSA has been shown to improve the specificity of PSA in the early detection of prostate cancer since patients with prostate cancer have higher levels of PSA-ACT than do patients with BPH (Stenman et al., Cancer Res.
35 51:222-26 (1991) and Stenman et al., Lancet 334:1594-1598 (1994)).

Additionally, it should be noted that the PSA peptides of the present invention can be used either alone or attached to a carrier such as a protein (for example, bovine serum albumin, keyhole limpet hemocyanin or ovalbumin) or to a chemical backbone (for example, poly-L-lysine or poly-L-glutamine). In a competitive assay, the peptide or peptide carrier can be used in place of PSA to inhibit the anti-PSA peptide antibody as a control (or as a calibrator) for the assay. For a sandwich assay, two peptides bound to a common carrier backbone can be used to generate a bivalent molecule containing two peptides (bivalent peptide control or calibrator) that can sandwich in an assay using antibodies to these two peptides. During the use of these artificial controls, the bivalent peptide control is included as a sample, and its level is monitored for assay validity. Furthermore, with respect to the use of the bivalent peptides as calibrators, various concentrations of the bivalent peptides may be used to generate a calibration curve for the assay. Potential advantages are stability, cost of manufacture and the use of a very defined control or calibrator.

20

Furthermore, peptides having sequences of regions of hK2 can be used to generate hK2 specific antibodies in polyclonal and monoclonal systems by injection with peptide-carrier proteins or in other immunogenic forms. Additionally, immunoassays specific for hK2 may be configured using a combination of these hK2 specific antibodies or one of these antibodies in combination with a total PSA antibody if it is hK2 cross-reactive. More specifically, a sandwich assay format using one or two hK2 specific antibodies or one hK2 specific antibody assay could be generated with one hK2 specific antibody and labelled hK2 or hK2 peptide (see WO 95/03334). Thus, all of the above assays can be carried out with hK2 peptides which correspond to the regions of the PSA molecule from which the peptides of the invention were selected.

35

Additionally, it should be noted that the hK2 peptides, referred to above, can be used singly or in combination alone or

attached to a protein, such as bovine serum albumin, keyhole
limpet hemocyanin, or ovalbumin, or to a chemical backbone, such
as poly-L-lysine or poly-L-glutamine. In a competitive assay ,
the peptide or peptide carrier could be used to inhibit the anti-
5 hK2 peptide antibody as a control (or as a calibrator) for the
assay. For a sandwich assay to hK2, two hK2 peptides bound to a
common carrier backbone could be used to generate a bivalent
peptide control or calibrator that could sandwich in an assay
using antibodies to these two peptides. During this use as an
10 artificial control, the bivalent peptide control is included as a
sample and its level monitored for assay validity. With respect
to the use of the bivalent peptides as calibrators, various
concentrations of the bivalent peptides may be used to generate a
calibration curve for the assay. Potential advantages are
15 stability, cost of manufacture and the use of a very defined
control or calibrator.

It should also be noted that polyclonal antibodies produced
against PSA contain antibodies reactive with both free and total
20 PSA. The free specific antibodies in the polyclonal anti-PSA
antibody can be bound to a column containing the free specific
peptides of the current invention (e.g., ABT6 or ABT1) attached
to a solid phase, such as, for example, Cyanogen Bromide
Activated Sepharose CL4B. (For a general discussion of the
25 purification of antisera on peptide columns, see Methods in
Molecular Biology, ed. M. Manson, Vol. 10, pp. 39-41 (1992).)
The non-free peptide specific antibody is washed through the
column with buffer. The free specific antibodies are then eluted
with high or low pH or chaotropic agents to yield free specific
30 polyclonal antibodies which can be used in assays for free PSA.

Alternatively, epitope specific antibodies to total PSA can
be purified from polyclonal antisera. For example, peptides
ABT4, ABT14, or ABT16 can be bound to a solid phase carrier and
35 used to produce a column. The polyclonal antibodies reactive
with the peptide bind to the peptide on the column, while non-
reactive peptides are washed through the column with buffer. The

bound polyclonal antibodies are then eluted with high or low pH or chaotropic agents to yield peptide epitope specific polyclonal antibodies. These antibodies can be used in immunoassays to generate assays that can react equally to both free PSA and PSA-
5 ACT, in contrast to current sandwich assays polyclonal assays that have a bias towards free PSA (see copending U.S. patent application no. 08/174,964). Since the proportion of free PSA and PSA-ACT varies from person to person, there is a theoretical advantage of measuring free PSA and PSA-ACT equally (McCormack et
10 al., Urology 45:729-44 (1995), Stamey et al., Cancer 74:1662-66 (1994) and Stamey, Urology 45:173-84 (1995)).

It should also be noted that the anti-PSA antibodies created using the peptides of the present invention can be used to detect
15 PSA in frozen or paraffin sections of normal, benign or cancerous tissues or cell lines by way of immunohistochemical methods. For example, the labeled antisera may be added to the sample of interest, followed by an incubation and wash step. (Examples of suitable labels include, but are not limited to, an enzyme such
20 as alkaline phosphatase, glucose oxidase or peroxidase, a radiolabel such as I¹²⁵, or a fluorochrome such as fluorescein isothiocyanate.) Presence of PSA is then assessed by detection of absorbance from chromophore for the enzyme-labelled antibody, detection of radiodecay for the radiolabeled antibody, or
25 detection of fluorescence for the fluorochrome labeled antibody. Other labels and detection methods may also be used.

Additionally, since the peptides of the present invention elicit antibodies, the peptides may also be used in mammalian
30 vaccines.

The present invention can be illustrated by the use of the following nonlimiting examples:

35

EXAMPLE I

DESIGN, SYNTHESIS, AND EPITOPE MAPPING OF THE PEPTIDES

A. Peptide Design Strategy:

The potential peptide epitopes were designed based on a molecular model of PSA and amino acid sequence alignment (Bridon et al., Urology 45:801 (1995) & Vihinen, M., Biochem. Biophys. Res. Commun. 204:1251-1256 (1994)). The locations of sixteen peptides designed from the three dimensional model of PSA are shown in Figure 1A. The original protein sequence alignment of PSA and hK2 was obtained by Pileup from the Wisconsin Sequence Analysis Package (Genetic Computer Group, University Research Park, 575 Science Drive, Suite B, Madison, Wisc.). These alignments were then further edited according to the more accurate method of comparative modeling as described by Greer (J. Greer, Proteins 7:317 (1990)). The final protein sequence alignment of hK2 and PSA is shown in Figure 1B.

As noted above, sixteen PSA peptides were generated based on the primary amino acid sequence of PSA and the location of these peptides in the 3D model. Generally, these peptide sequences were surface accessible on the PSA molecule and showed certain secondary structural features, such as a protruding loop, an alpha-helix or a beta-turn. In addition, most of the designed peptides (i.e., 15/16) contained one or more amino acid residues that were different from human Kallikrein-1 (hK2).

B. Peptide Synthesis:

Designed peptides were synthesized by the stepwise solid-phase method of Merrifield (Merrifield, R.B., J. Am. Chem. Soc. 85:2149-2154 (1963)) on Applied Biosystem 431A Synthesizer (Foster City, CA) using standard Fmoc (9-fluorenylmethoxycarbonyl) chemistry. Peptides were cleaved and deprotected with a mixture of 82% TFA, 5% phenol, 5% H₂O, 5% thioanisole and 2.5% ethanedithiol for 2-4 hours at 25 °C and precipitated by addition of cold ether. Crude peptides were purified by reverse phase HPLC using a 5-50% acetonitrile gradient containing 0.1% TFA. The homogeneity and identity of the purified peptides were confirmed by electro-spray mass

spectrometry analysis. All peptides were determined to be at least 95% pure. In order to cyclize the peptides, peptides were generated which had one cysteine residue added to the carboxyl and amino terminals. Cyclic peptides formed by an intramolecular disulfide bridge were synthesized using the air oxidation method previously described (Tam et al., Proc. Natl. Acad. Sci. USA 83:8082-8086 (1986)). Briefly, purified linear peptides were dissolved in 0.1 mM Tris-HCl buffer (pH 8.4) at a concentration of 0.5 mg/ml and stirred at 25 °C for varying periods of time while exposed to air. HPLC was used to monitor the completion of oxidation. Cyclic peptides were purified as described above, and the formation of intramolecular disulfide bonds was confirmed by electro-spray mass spectra.

15 C. Epitope Mapping:

I. Indirect ELISA

An indirect ELISA assay was used to determine the reactivity and specificity of anti-PSA mAbs and pAbs. For the assay, 96 well microtiter plates (Costar, Cambridge, MA) were coated with PSA (0.5 micrograms/well, Abbott Laboratories, in house product, code# 91969, purified from seminal fluid) or peptides (0.1 mg/well) in 0.1 M carbonate-bicarbonate buffer (pH 9.0) overnight at 4 °C. The plates were blocked with 1% BSA in PBS buffer (0.008 M sodium phosphate, 0.002M potassium phosphate, 0.14 M sodium chloride and 0.01M potassium chloride, pH 7.4) for 1 hour, then anti-PSA mAbs or pAbs (100 microliters/well) at varying dilutions were added. After incubation for 1 hour at 25 °C, the wells were washed with PBS buffer containing 0.5% Tween 20, then 100 microliters/well of alkaline phosphatase-conjugated antibody (goat anti-mouse IgG or goat anti-rabbit IgG -- from Pierce, Rockford, IL) at 5000 fold dilution was added and incubation continued for 1-2 hr at 25 °C. After washing, 100 microliters/well of p-nitrophenyl phosphate substrate (Pierce, Rockford, IL) was added and the absorbance was measured at 405 nm using an automated microtiter plate reader (Molecular Devices Corp. Menlo Oaks, CA).

II. Competitive Immunoassays

(A). Two-site combinations of capture antibody and Europium chelate (Eu)-labeled antibody was used to determine the inhibition of mAbs binding to PSA by the synthetic peptides derived from PSA. Briefly, free PSA (0.05 pmol/well, Wallac, OY, Turku, Finland) in 0.100 mL of Delfia® buffer (Wallac, OY) (i.e., a blocking buffer containing 50 mM Tris-HCl (pH 7.75), 0.9% NaCl, 0.05% Na-azide, 0.01% Tween 40, 0.05% bovine-gammaglobulin, 20 µM DTPA, 0.5% BSA, 10 µg/mL native mouse IgG, 5 µg/mL denatured mouse IgG and 20 µg/mL cherry red) was added to microtiter wells coated with the various anti-PSA antibodies being used for capture (1-2 µg/well of antibody) and incubated for 1 hour at 25 °C. (Free or total antibodies may be used.) After washing with Delfia® wash solution, peptides (62,500-1,000,000 molar excess to PSA) in 25 mL Delfia® buffer were added together with the Europium chelate-labeled anti-PSA antibody (0.05 pmol), and incubation was continued for 1 hour at 25 °C. After another four washings, the amount of bound Eu-labeled antibody was determined with time-resolved fluorometry previously described (Pettersson et al., Clin. Chem. 41:1480-88 (1995) & Hemmilia et al., Anal. Biochem. 137:335-43 (1984)).

(B). Two-site combinations of capture antibody and alkaline phosphatase-conjugated antibody were also used to determine the inhibition of mAbs binding to PSA by the synthetic peptides, using alkaline-phosphatase labelled antibodies. Combinations of probe and capture antibodies, which included antibodies with specificities for either free or total PSA, were chosen so that these combinations could bind to form a sandwich. As described above, various anti-PSA capture mAbs (i.e., either free or total) (0.4 pmol/well) in 100 ml PBS buffer (pH 7.4) were added to coated microtiter wells (1 µg/well) and incubated for 1 hour at 25 °C. After washing with PBS buffer containing 0.5% Tween 20, peptides were added (50,000-500,000 molar excess to PSA) in 50 µl PBS buffer together with alkaline phosphatase-conjugated antibody (20 ng/well, Abbott Laboratories) and incubated for 1-2

hr at 25 °C. After another four washings, 100 µl/well of p-nitrophenyl phosphate substrate (Pierce Chemical Co., Rockford, IL) was added and the absorbance was measured at 405 nm using an automated microtiter plate reader.

5

D. Results:

I. Epitopes of mAbs preferentially binding to free PSA:

All sixteen synthetic peptides (Table 1) were screened with a series of monoclonal anti-PSA antibodies using a competitive immunoassay described in section C-II-A. ABT6 peptide showed specific binding to mAb 9B10 and 5A10 that are specific for free PSA (Lilja et al., Clin. Chem. 37:1618-25 (1991), Pettersson et al., Clin. Chem. 41:1480-88 (1995) & Lovgren et al., Biochem. Biophys. Res. Commun. 213:888-95 (1995)). ABT6 peptide also selectively bound to mAb 2E9 (Lovgren et al., Biochem. Biophys. Res. Commun. 213:888-95 (1995)) and H68 (obtained by Abbott Labs.) which binds a region close to that covered by ACT in the PSA-ACT complex. The percent inhibition of the mAbs binding to PSA by the ABT6 peptide is shown in Figure 2A. These data demonstrate that ABT6 contain an epitope on PSA recognized by the mAbs specific for free PSA or that show preferential binding to free PSA.

As shown in Figure 1B, ABT6 peptide contains several amino acids which are different from the hK2 sequence. To demonstrate that the ABT6 peptide represents a PSA specific epitope, the corresponding hK2b peptide (see Figure 1B) was synthesized. The specific binding of ABT6 peptide, hK2 peptides and PSA to mAb 2E9 were compared using indirect ELISA as described in section C-I. Figure 2B shows the ELISA results. It is clear that 2E9 shows specific binding to both PSA and ABT6 peptide, but not to hK2 peptide. Based on these data, it is concluded that ABT6 peptide, which is a protruding loop on the 3D model of PSA, represents a PSA specific epitope that will be blocked or sterically hindered by the binding of ACT to PSA in the PSA-ACT complex. In addition, this epitope has some specificity to PSA, based on comparisons between ABT6 and hK2b.

II. Epitopes of mAbs specific for total PSA:

Three synthetic peptides, ABT4, ABT14 and ABT16 were identified to contain epitopes of several mAbs that were specific for total PSA in the competitive immunoassays described in section C-II-A and B. ABT4 peptide inhibits 80 to 90% PSA binding to mAb 2C1 (Lovgren et al., Biochem. Biophys. Res. Commun. 204:1251-56 (1994)) and H164 (produced by standard hybridoma techniques at Abbott Labs., Abbott Park, Illinois), respectively (Figure 3A). ABT14 selectively inhibits PSA binding to mAb 4H5 (Lovgren et al., Biochem. Biophys. Res. Commun. 204:1251-56 (1994)), and ABT16 inhibits PSA binding to mAb P10 (CanAg Diagnostics Inc., Gothenberg, Sweden), and H50 (produced by standard hybridoma techniques at Abbott Labs., Abbott Park, Illinois) (Figure 3B). However, the percent inhibition of both peptides was relatively weak compared to ABT4 peptide. Thus, ABT14 and ABT16 may represent partial epitopes of mAb 4H5, P10 and H50.

From the sequence alignment (Figure 1B), the potent ABT4 peptide contained several amino acids that were different from the hK2 sequence. To evaluate the epitope specificity of the ABT4, the corresponding hK2a peptide was synthesized. The specific binding of ABT4, hK2a peptides (see Figure 1B) and PSA to mAb H164 was determined using indirect ELISA as described in section C-I, and the results are shown in Figure 3C. These data (Figure 3C) demonstrated that MAb H164 bound specifically to PSA and PSA peptide ABT4, but not to the hK2a peptide. Therefore, ABT4, which exhibited a loop and beta-strand structure on the 3D model of PSA, represented a PSA specific epitope and this epitope will not be blocked by ACT in the PSA-ACT complex.

III. Anti-PSA pAb reactivity against synthetic peptides:

Synthetic peptides were also screened by a direct ELISA assay format which utilized a goat anti-PSA antiserum conjugated to alkaline phosphatase. In particular, peptides were coated on microtiter plates and detected by enzyme-labelled anti-PSA

polyclonal antibodies. The goat anti-PSA antiserum was produced by immunization with free PSA. As a polyclonal antisera, this goat anti-PSA can be expected to exhibit antibodies to multiple free and total PSA associated epitopes. The ELISA results are shown in Figure 4. In addition to those epitopes identified by mAbs as described above, two new epitopes, ABT2 and ABT7, were identified by the anti-PSA antiserum.

EXAMPLE II

IMMUNOGENICITY OF ABT6 PEPTIDE (Free PSA epitope)

A. Immunization with ABT6 peptide

Antiserum was elicited by immunizing rabbits with PSA peptide ABT6 coupled to the carrier protein KLH (keyhole limpet hemocyanin) at Bio-Synthesis, Inc. (Lewisville, Texas) using standard commercially available techniques.

B. Reactivity and specificity of anti-ABT6 antiserum

The reactivity and specificity of antiserum anti-ABT6 was evaluated by estimating the relative binding affinities (Wang et al., Urology 39:1-5 (1982)) for PSA, PSA peptide ABT6 and hK2 peptide hK2b as described in Example I. The indirect ELISA format described in Section C-I of Example 1 was used for these studies and the data are shown in Figure 5. These data demonstrated that the anti-ABT6 antiserum specifically bound only to ABT6 peptide and PSA with high affinity. There is almost no binding for the hK2b peptide.

EXAMPLE III

IMMUNOGENICITY OF ABT4 PEPTIDE (Total PSA epitope)

A. Immunization with ABT4 peptide

Anti-ABT4 antiserum was elicited by immunizing two rabbits with PSA peptide ABT4 coupled to the carrier protein KLH at Bio-Synthesis, Inc. (Lewisville, Texas).

B. Reactivity and specificity of anti-ABT4 antiserum

The reactivity and specificity of Anti-ABT4 antiserum were evaluated by estimating the relative binding affinities (Wang et al., Oncology 39:1-5 (1982)) for PSA, PSA peptide ABT4 and hK2 peptide (hK2a) as described in Example I. The indirect ELISA assay format described in Section C-I of Example I was used for these studies and the data are shown in Figure 6. These data demonstrated that although the anti-ABT4 antiserum binds to both ABT4 peptide and PSA, there is some cross reactivity with the hK2A peptide. The relative affinity was $ABT4 > PSA > hK2a$.

CLAIMS:

1. A purified peptide comprising an amino acid sequence of
5 approximately 10-20 residues wherein said sequence is identical
to the amino acid sequence of a region of Prostrate Specific
Antigen (PSA) and comprises one or more amino acids nonidentical
to the amino acid sequence of human glandular kallikrein (hK2).

10 2. The purified peptide of claim 1 wherein said peptide is
selected from the group consisting of ABT1 (SEQ. ID. No:1),
ABT2 (SEQ. ID. No:2), ABT3 (SEQ. ID. No:3), ABT4 (SEQ. ID. No:4),
ABT5 (SEQ. ID. No:5), ABT6 (SEQ. ID. No:6), ABT7 (SEQ. ID. No:7),
ABT8 (SEQ. ID. No:8), ABT9 (SEQ. ID. No:9), ABT10 (SEQ. ID. No:10),
15 ABT11 (SEQ. ID. No:11), ABT12 (SEQ. ID. No:12), ABT13 (SEQ. ID.
No:14), ABT15 (SEQ. ID. No:15) and ABT16 (SEQ. ID. No: 16).

3. The purified peptide of claim 2 wherein said peptide is
selected from the group consisting of ABT2, ABT4, ABT6, ABT1,
20 ABT7, and ABT16.

4. An antibody specific for free PSA produced in response
to immunization by a peptide selected from the group consisting
of ABT6 and ABT1.
25

5. The antibody of claim 4 wherein said antibody is
monoclonal.

6. The antibody of claim 4 wherein said antibody is
30 polyclonal.

7. An antibody specific for total PSA produced in response
to immunization by a peptide selected from the group consisting
of ABT4, ABT14 and ABT16.
35

8. The antibody of claim 7 wherein said antibody is
monoclonal.

9. The antibody of claim 7 wherein said antibody is polyclonal.

5 10. A method for detecting PSA in a test sample suspected of containing PSA comprising the steps of:

a) contacting the test sample with an antibody or fragment thereof which specifically binds to at least one site on a
10 peptide or antigen for a time and under conditions sufficient to allow for the formation of antigen/antibody complexes

wherein said peptide or antigen comprises an amino acid sequence of approximately 10-20 residues wherein said sequence is
15 identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2;

b) adding a probe antibody to said resulting
20 antigen/antibody complexes for a time and under conditions sufficient to allow said probe to bind to bound antigen, wherein said probe binds to a second site on said peptide or antigen; and

c) determining the amount of bound probe and thus the
25 amount of PSA in said test sample.

11. The method of claim 10 wherein said antibody of step (a) is attached to a solid phase.

30 12. The method of claim 10 wherein said antibody of step (b) is labelled with a radioactive isotope.

13. The method of claim 10 wherein one antibody is specific for free PSA and the other antibody is specific for total PSA, or
35 both antibodies are specific for total PSA.

14. The method of claim 10 wherein said peptide or antigen is selected from the group consisting of
selected from the group consisting of ABT2, ABT4, ABT6, ABT1, ABT7, and ABT16.

5

15. A method of detecting PSA in a test sample suspected of containing PSA comprising the steps of:

10 a) contacting the test sample with an antibody or fragment thereof which specifically binds to at least one peptide or antigen derived from PSA for a time and under conditions sufficient to allow for the formation of antigen/antibody complexes

15 wherein said peptide or antigen comprises an amino acid sequence of approximately 10-20 residues wherein said sequence is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2;

20

b) adding a labeled free PSA to said resulting test sample-antibody mixture of step (a); and

25 c) determining the amount of PSA in the test sample by assessing the amount of competition between the PSA in the test sample and the labelled free PSA.

16. The method of claim 15 wherein, if free PSA is to be detected, said antibody of step (a) binds specifically to free
30 PSA, and if total PSA is to be detected, said antibody of step (a) binds to total PSA.

17. The method of claim 15 wherein said peptide or antigen is selected from the group consisting of ABT2, ABT4, ABT6, ABT1,
35 ABT7, and ABT16.

18. A kit for determining the presence of PSA in a test sample comprising a container containing an antibody produced in response to immunization by a peptide which comprises an amino acid sequence of approximately 10-20 residues wherein said
5 sequence is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2.

19. The kit of claim 17 wherein said peptide is selected
10 from the group consisting of ABT2, ABT4, ABT6, ABT1, ABT7, and ABT16.

20. A kit for determining the presence of PSA in a test sample comprising:

15

a) an antibody or fragment thereof which specifically binds to at least one site on PSA

wherein said antibody or fragment thereof is produced in
20 response to immunization by a peptide comprising an amino acid sequence of approximately 10-20 residues wherein said sequence is identical to the amino acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2; and

25

b) a probe antibody wherein said probe binds to a second site on said PSA.

21. The kit of claim 20 wherein peptide is selected from
30 the group consisting of ABT2, ABT4, ABT6, ABT1, ABT7, and ABT16.

22. A kit for determining the presence of free PSA in a test sample comprising:

35 a) an antibody or fragment thereof which specifically binds to a peptide comprising an amino acid sequence of approximately 10-20 residues wherein said sequence is identical to the amino

acid sequence of a region of PSA and comprises one or more amino acids nonidentical to the amino acid sequence of hK2; and

b) labeled free PSA.

5

23. The kit of claim 22 wherein said peptide is ABT6.

24. A purified peptide comprising an amino acid sequence of approximately 10-20 residues wherein said sequence is identical
10 to the amino acid sequence of a region of PSA and identical to the amino acid sequence of a region of hK2.

25. The peptide of claim 24 wherein said peptide is ABT14.

1/8




FIG. 1A

2/8

48
1 IVGWECEKH SQPWQVAVYS H.GWAHCGGV LVHPQWVLT A AHCLK.KNSQ
HK2 IVGWECEKH SQPWQVAVYS H.GWAHCGGV LVHPQWVLT A AHCLK.KNSQ
PSA IVGWECEKH SQPWQVAVYS H.GWAHCGGV LVHPQWVLT A AHCLK.KNSQ
|-----ABT14-----|
|-----ABT12-----|

50
|-----hk2a-----|
VWLGRHNLFE .PEDTGQVVP VSHSFPHPLY NMSLLKHQSL RPDEDSSHDL
HK2 ILLGRHSLFH .PEDTGQVFP VSHSFPHPLY DMSLLKNRFL RPDGDDSSHDL
PSA |C-----ABT4-----C|
|-----ABT10-----|
|C-----ABT1-----C|

99
MLRLSEPAK ITDVVKVLGL PT..QEPALG TTCYASGWGS IEPEE..FLR
HK2 MLRLSEPAK ITDVVKVLGL PT..QEPALG TTCYASGWGS IEPEE..FLR
PSA MLRLSEPAK ITDVVKVLGL PT..QEPALG TTCYASGWGS IEPEE..FLR
|-----ABT7-----|
|-----ABT11-----|
|-----ABT17-----|

146
PRSLQCVSLH LLSNDMCARA YSEKVTEFML CAGLWTGGKD TCGDSDGGPL
HK2 PRSLQCVSLH LLSNDMCARA YSEKVTEFML CAGLWTGGKD TCGDSDGGPL
PSA PKKLQCVDLH VISNDVCAQV HPQKVTKFML CAGRWTGGKS TCGDSDGGPL
|-----C|
|-----ABT3-----|
|-----ABT15-----|
|-----ABT16-----|
|-----ABT9-----|

237
196
VCN.....GVL QGITSWGPEP CALP.EKPAV YTKVVHYRKY IKDTIAANP
HK2 VCN.....GVL QGITSWGPEP CALP.EKPAV YTKVVHYRKY IKDTIAANP
PSA VCN.....GVL QGITSWGPEP CALP.EKPAV YTKVVHYRKY IKDTIAANP
|-----ABT5-----|
|-----ABT8-----A|

FIG. 1B

3/8




FIG. 2A




FIG. 2B

4/8




FIG. 3A




FIG. 3B

5/8




FIG. 3C

6/8




FIG. 4

7/8




FIG. 5

8/8




FIG. 6



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/57, C07K 16/40, G01N 33/573, C12N 9/64	A3	(11) International Publication Number: WO 97/29199 (43) International Publication Date: 14 August 1997 (14.08.97)
(21) International Application Number: PCT/US97/01911 (22) International Filing Date: 6 February 1997 (06.02.97) (30) Priority Data: 08/595,945 6 February 1996 (06.02.96) US (71) Applicant: ABBOTT LABORATORIES [US/US]; CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US). (72) Inventors: DOWELL, Barry, Lee; 197 Knightsbridge Drive, Mundelein, IL 60060 (US). BRIDON, Dominique, P.; 2167 Bay Street, San Francisco, CA 94123 (US). QIU, Xiaoxing; 752 Sierra Place, Gurnee, IL 60031 (US). LILJA, Hans; Holländarevagen 28, S-236 00 Hollviken (SE). PIRO- NEN, Timo, Petteri; Frantsinkatu 4 B 8, FIN-20380 Turku (FI). VIHINEN, Mauno, Antero; Alkutie 27 C, FIN-00660 Helsinki (FI). PETTERSSON, Immanuel, Kim, Sverker; Ti- lentekijankatu 14 E 20, FIN-20810 Turku (FI). (74) Agents: BECKER, Cheryl, L. et al.; Abbott Laboratories, CHAD 0377/AP6D-2, 100 Abbott Park Road, Abbott Park, IL 60064-3500 (US).		(81) Designated States: CA, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims</i> <i>and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 26 February 1998 (26.02.98)
(54) Title: PROSTATE SPECIFIC ANTIGEN PEPTIDES AND USES THEREOF (57) Abstract <p>The present invention relates to peptides which may be used, for example, in the detection of free and complexed Prostate Specific Antigen and thus in the diagnosis of prostate cancer.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 97/01911

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C12N15/57 C07K16/40 G01N33/573 C12N9/64

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 94 03205 A (CYTEL CORPORATION) 17 February 1994 see page 53; example 8 ---	1,24
X	WO 94 20127 A (CYTEL CORPORATION) 15 September 1994 see page 87; table 25 ---	1,24
P,X	WO 96 40754 A (BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM) 19 December 1996 see page 42; claims; examples ---	1-6
A	---	10-22
A	WO 92 01936 A (LILJA HANS) 6 February 1992 cited in the application ---	10-22

	-/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

S document member of the same patent family

Date of the actual completion of the international search

17 December 1997

Date of mailing of the international search report

16.01.98

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Le Cornec, N

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/01911

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	D.P. BRIDON ET AL: "Structural comparison of Prostate-specific antigen and human glandular kallikrein using molecular modeling" UROLOGY, vol. 45, no. 5, May 1995, pages 801--806, XP002037490 cited in the application see page 803; figure 1 see page 804	1-6, 10-22,24
X	--- KIM PETTERSON ET AL: "Free and complexed Prostate-specific-antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha1-antichymotrypsin complex" CLINICAL CHEMISTRY, vol. 41, no. 10, 1995, WINSTON US, pages 1480-1488, XP002037491 cited in the application see the whole document see page 1483; figure 1	4-6,8
A	---	10-22
X	LOEVGREN J ET AL: "PRODUCTION OF RECOMBINANT PSA AND HK2 AND ANALYSIS OF THEIR IMMUNOLOGIC CROSS-REACTIVITY" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 213, no. 3, 24 August 1995, pages 888-895, XP000605371 cited in the application see the whole document see figure 1; table 2 see page 893	4-6
A	---	10-22
T	EL-SHIRBINY A M: "PROSTATIC SPECIFIC ANTIGEN" ADVANCES IN CLINICAL CHEMISTRY, vol. 31, 1994, pages 99-133, XP000617158	
T	--- E. COREY ET AL: "Prostate-specific antigen: characterization of epitopes by synthetic peptide mapping and inhibition studies" CLINICAL CHEMISTRY., vol. 43, no. 4, April 1997, WINSTON US, pages 575-584, XP002050580	

3

-/--

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 97/01911

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	V. KRCHNAK ET AL: "Computer prediction of B-cell determinants from protein amino acid sequences based on incidence of beta-turns" METHODS IN ENZYMOLOGY, vol. 178, 1989, pages 586-611, XP002050581	
A	<p>---</p> <p>H. LILJA ET AL: "Prostate-specific antigen in serum occurs predominantly in complex with alpha-antichymotrypsin" CLINICAL CHEMISTRY, vol. 37, no. 9, 1991, WINSTON US, pages 1618-1625, XP000619911 cited in the application see the whole document</p> <p>-----</p>	4-6,8, 10-22

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 97/01911

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☒ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Form PCT/ISA/210 (continuation of first sheet (1)) (July 1992)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

1) claims : (1-6,10-23) totally and (7-9) partially : Peptides (ABT1- ABT13, ABT15 and ABT16) all comprising an amino acid sequence of a region of Prostate Specific Antigen (PSA) and having one or more amino acids nonidentical to the amino acid sequence of human glandular kallikrein(hK2). Antibodies and use of the antibodies in diagnosis.

2) claims : (7-9) partially; 24-25 totally : Peptide ABT14 comprising an amino acid sequence of a region of Prostate specific Antigen (PSA) identical to the amino acid sequence of a region of hK2. Antibody.

INTERNATIONAL SEARCH REPORT

information on patent family members

International Application No

PCT/US 97/01911

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9403205 A	17-02-94	AU 4998993 A	03-03-94
		CA 2141960 A	17-02-94
		EP 0656788 A	14-06-95
		JP 8500106 T	09-01-96
		NZ 255683 A	27-08-96
		US 5662907 A	02-09-97

WO 9420127 A	15-09-94	AU 6359494 A	26-09-94
		BR 9406652 A	10-09-96
		CA 2157510 A	15-09-94
		CN 1118572 A	13-03-96
		EP 0703783 A	03-04-96
		JP 8507525 T	13-08-96

WO 9640754 A	19-12-96	AU 6095696 A	30-12-96

WO 9201936 A	06-02-92	AT 134448 T	15-03-96
		DE 9117047 U	18-05-95
		DE 69117292 D	28-03-96
		DE 69117292 T	18-07-96
		DE 540573 T	28-09-95
		EP 0540573 A	12-05-93
		ES 2070107 T	01-06-95
		JP 6502719 T	24-03-94
US 5501983 A	26-03-96	-----	

Form PCT/ISA/210 (patent family annex) (July 1992)